Resolution criteria

This market resolves YES if Abbott Laboratories acquires Exact Sciences at a price of $100 or more per share by November 26th. Resolution will be based on the official acquisition price announced by both companies. The acquisition price should be verified through official press releases from Abbott and Exact Sciences, SEC filings (8-K forms), or major financial news sources such as Bloomberg, Reuters, or the Wall Street Journal. If the deal is terminated or fails to close, the market resolves NO.

Background

Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., in what could be the biggest deal of the year in the global health-care sector. The potential acquisition would give Abbott entry into the fast-growing oncology diagnostics market, leveraging Exact Sciences' strong brand power for products like Cologuard and Oncotype. Analyst estimates suggest the deal could value Exact Sciences at $20 billion or more, which would represent approximately $100 per share or higher. Exact Sciences stock was trading near its 52-week high of $72.81 before acquisition reports emerged.

Considerations

Deliberations are ongoing and could still be delayed or falter. The final acquisition price has not yet been disclosed, and analyst valuations suggesting $100+ per share represent estimates based on typical acquisition multiples rather than confirmed terms. Regulatory approval may be required, and the deal structure could involve cash, stock, or a combination of both, which could affect the per-share valuation.